VitaVitro Biotech Completes Series B Financing to Expand as a Global ART Solutions Provider

VCBeat (WeChat ID: vcbeat) has learned that Shenzhen VitaVitro Biotech Co., Ltd. (hereinafter referred to as “VitaVitro”) recently announced the completion of its Series B financing, jointly invested by DaoTong Investment and Weilai Zhuoshi. The specific amount raised was not disclosed, and the proceeds will be primarily used for research and development as well as channel expansion.

Vitro Biotech, established in 2015, is a National High-Tech Enterprise and an upstream supplier of technologies and products in the field of assisted reproduction. The company is committed to providing cutting-edge technologies for assisted reproduction and delivering integrated solutions to assisted reproductive laboratories worldwide. Its products are sold across major global regions, including Europe, the Americas, and the Asia-Pacific.

From 2007 to 2013, in vitro fertilization (IVF) technology contributed approximately 2.5 million births worldwide. By 2017, the global number of IVF-conceived individuals had reached around 8 million, with a compound annual growth rate maintained at 10%–15%. In vitro fertilization has become the primary method for treating infertility.

In 2017, there were approximately 47.7 million couples with infertility in China, and this number is projected to rise to around 56.2 million by 2023. Data released by the China Population Association and the National Health and Family Planning Commission show that the infertility rate among couples of childbearing age in China has climbed from 2.5%–3% two decades ago to approximately 12%–15% in recent years, affecting more than 50 million individuals. Infertility is becoming a major health condition threatening human well-being. Embryology laboratory technologies and products are among the critical factors determining the success or failure of assisted reproductive technology (ART).

The ability to maintain smooth financing is inseparable from Weituo Bio's gradually established international brand image.

This can be traced back to the company’s initial strategic decision to enter the assisted reproductive technology (ART) sector through the European and American markets, marking the beginning of its internationalization. In 2017, Weito Bio launched a new brand to expand into the global market, with flagship products featuring leading-edge R&D capabilities and technological differentiation. This has been a key strategy enabling large-scale entry into the international market.

In addition to innovations in R&D and technology, Weituo Bio emphasizes quality control during the production process. Some of its products have obtained NMPA, FDA, and CE certifications, with product standards and quality systems complying with global medical device regulatory requirements.

Countries and Regions Covered by Weituo Bio’s Business Operations 

Over the past two years of cultivating the international market, Weituo Bio has actively expanded its overseas presence, establishing brand influence and distribution channels in the Middle East, Southeast Asia, Central Asia, the United States, Eastern Europe, Northern Europe, the United Kingdom, Russia, India, Brazil, and other regions. The company has steadily enhanced its global brand recognition, delivering advanced technologies and products to an growing number of customers across various countries and regions.

The first “brick” in building Weituo Biotech’s integrated solution for assisted reproduction is its vitrification and warming protocol. Chief Scientist Professor Vajta is a renowned expert in the field of global assisted reproduction, with significant achievements in the cryopreservation and culture of oocytes and embryos.

The two products developed by Weituo Biotech, vitrification freezing solution and vitrification thawing solution, are the first domestically developed products to obtain U.S. FDA 510(k) clearance, and have been marketed in the United States for two years. The company is currently actively conducting clinical trials and scientific research collaborations related to its vitrification freezing and thawing solutions in China.

Since launching its first product in 2018, Weituo Biotech has consistently secured regulatory approval for two to three new products annually, and currently offers a comprehensive portfolio of solutions for embryology laboratories in overseas markets.

 Weituo Bio Attends International Assisted Reproductive Technology Exhibition

In addition to its products, the company provides professional guidance and services related to assisted reproduction to medical institutions (or physicians). Improving the success rates of assisted reproductive technologies has always been a core commitment of Weituo Bio. Its comprehensive marketing system, after-sales service network, and sustainable R&D capabilities constitute the core competitiveness of Weituo Bio in the international market.

Notably, in addition to its focus on human assisted reproduction, Weituo Bio has also established a presence in the livestock industry, leveraging China’s Belt and Road Initiative to provide breeding preservation services and products for the livestock sectors in the Middle East and East Asia.

Facing China’s vast assisted reproductive technology (ART) market, Weituo Biotech has begun expanding its domestic operations this year while maintaining its overseas presence. The company has already established collaborations with several key clinical institutions in China and has earned high recognition from clinicians.

This Series B financing round officially marked the commencement of Weituo Biotech’s expansion into the domestic Chinese market, with a commitment to providing advanced technological products and research support to local healthcare professionals.

Regarding the investment in Weituo Bio,Sun Qi, Founding Managing Partner of Daotong Investmentstated: “Women’s and children’s health has always been a key focus area for Daotong Investment. Driven by demographic shifts in China and other societal factors, fertility issues are garnering increasing public attention. The infertility rate in China is rising rapidly, fertility rates among women of optimal childbearing age are declining, and the number of advanced maternal age pregnancies has surged significantly. As assisted reproductive technology (ART) becomes the last resort, this has generated substantial demand in the ART market. Currently, the penetration rate of China’s ART market remains far below that of European and American markets, indicating significant growth potential.”

China has long faced a shortage of core reagents and consumables for assisted reproductive technology (ART) laboratories, with imported products accounting for more than 90% of the market share. The Weituo team has been deeply engaged in this field for many years, boasting leading capabilities in product R&D and commercialization, as well as a robust product pipeline. Currently, some of its products have successively obtained FDA and CE certifications, breaking the foreign technological monopoly and establishing a leading position in China. As Weituo’s products see broader application in the future, they will better meet domestic market demands and help more families.

Zhao Yang, Partner at Weilai CapitalIt stated: “The import substitution of domestic medical device reagents and consumables has been ongoing for many years, and this trend is expected to continue in numerous niche sectors in the future. Due to significant advantages in supply chain and channel operations, import substitution has already been achieved in the fields of cardiac stents and diagnostic consumables, with the domestic production rate rising from less than 10% to over 80%. The gap between leading overseas enterprises and their domestic competitors in the assisted reproductive technology (ART) industry is not substantial. Chinese companies possess unique capabilities in original technological innovation, offering them the opportunity to establish a global leading advantage by leveraging the vast Chinese market.”

Weituo Biotech’s products and technologies are industry-leading, with its R&D team ranking among the global elite. This is the core reason for our investment in Weituo. We believe that, in terms of technology, growth rate, and market size, the assisted reproductive technology (ART) reagents and consumables market closely resembles the Chinese in vitro diagnostics (IVD) market around 2014. The Chinese ART reagents and consumables market is growing at a rate of 20%, and is projected to reach a market size of over RMB 50 billion within the next five years. Furthermore, capital markets have been intensively investing in ART centers in countries surrounding China. Under this trend, Chinese manufacturers of ART reagents and consumables will experience a period of rapid growth driven by cross-border medical services.

Focused on early-stage investments and industrial M&A within the broader healthcare sector, with a particular emphasis on healthcare services and innovative medical technologies. The core team hails from the healthcare industry, bringing extensive experience in operational management and investment exits, including successfully incubating early-stage startups and managing publicly listed companies with market capitalizations in the tens of billions. Leveraging deep industry expertise and broad, high-quality sector resources, we provide robust post-investment value-added services to our portfolio companies. Selected investment cases include Lading Medical, Dayi Group, Deepwise Healthcare, and Weieruo Pediatrics.

Lai Capital focuses on early- to mid-stage investments in the consumer healthcare sector. Its cornerstone investor is By-Health (300146), and its team comprises seasoned professionals from the medical and healthcare industry. Investment areas include commercial health insurance, new retail models in pharmaceuticals, and medical devices. Leveraging deep industrial chain resources and extensive industry expertise, the fund provides comprehensive industrial empowerment to its portfolio companies. Selected investment cases include Jianyibao, Xiyou Health, and VCBeat.